Skip to main content
Cellectis S.A. (CLLS)
NASDAQ: CLLS · Real-Time Price · USD
4.000
-0.010 (-0.25%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Cellectis Revenue

In the year 2025, Cellectis had annual revenue of $79.59M with 61.72% growth. Cellectis had revenue of $12.21M in the quarter ending December 31, 2025, a decrease of -19.51%.

Revenue (ttm)
$79.59M
Revenue Growth
+61.72%
P/S Ratio
3.66
Revenue / Employee
$347,568
Employees
229
Market Cap
291.55M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 202579.59M30.38M61.72%
Dec 31, 202449.22M40.02M435.37%
Dec 31, 20239.19M-16.53M-64.26%
Dec 31, 202225.72M-12.87M-33.35%
Dec 31, 202138.60M-20.97M-35.20%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Compugen 72.76M
Coherus Oncology 42.17M
Editas Medicine 40.52M
C4 Therapeutics 35.95M
Zentalis Pharmaceuticals 26.87M
LENZ Therapeutics 19.09M
AC Immune 4.51M
Revenue Rankings

CLLS News

More News